Paraza Pharma

Executive Summary

Paraza Pharma is a fully integrated drug discovery research organization (DRO) based in Montreal, Canada, offering end-to-end discovery and development services to biotech, pharma, and academic partners. Founded in 2011, the company leverages deep expertise across chemistry, biology, and DMPK (drug metabolism and pharmacokinetics) to advance programs from concept to candidate. By providing integrated services, Paraza helps clients accelerate their drug development timelines while reducing costs and risks. The company's focus on small molecules and drug delivery positions it well within the competitive CRO/DRO landscape, catering to a growing demand for outsourced R&D. As a private entity, Paraza Pharma does not publicly disclose financials or pipelines, but its sustained presence since 2011 suggests steady operations and client retention. The drug discovery outsourcing market is expanding, driven by increasing R&D costs and the need for specialized expertise. Paraza's comprehensive service model and location in a biotech hub like Montreal provide competitive advantages. However, the lack of public information on specific client programs or financial performance makes it challenging to assess near-term growth. The company's success is tied to its ability to secure and retain partnerships, particularly with large pharma companies seeking flexible discovery support. Overall, Paraza Pharma appears to be a stable, well-positioned DRO with moderate growth prospects, contingent on its capacity to win new contracts and expand its service offerings in a competitive market.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major partnership with top-20 pharma company70% success
• H2 2026Expansion of Montreal facility or addition of new technology platform (e.g., AI-driven drug design)80% success
• Q4 2026Milestone payment from client program achieving candidate nomination60% success